Trevi Therapeutics(TRVI) - 2025 Q4 - Annual Results

Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates Exhibit 99.1 Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026 Company ended 2025 with $188.3 million in cash, cash equivalents ...